News
SXTPW
0.0300
-15.49%
-0.0055
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 23h ago
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 1d ago
Weekly Report: what happened at SXTP last week (0803-0807)?
Weekly Report · 2d ago
60 Degrees Pharmaceuticals Shareholders Approve Key Governance Actions
TipRanks · 5d ago
Merck KGaA (MKKGY) Misses Q2 Earnings Estimates
NASDAQ · 6d ago
60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital
TipRanks · 08/04 21:30
Weekly Report: what happened at SXTP last week (0727-0731)?
Weekly Report · 08/03 10:11
60 Degrees Pharmaceuticals Prices $1.0M Private Placement At $1.74 Per Share; Stock Down
NASDAQ · 07/31 15:00
60 Degrees Pharmaceuticals to sell shares and warrants in private placement
TipRanks · 07/30 18:35
60 Degrees Pharmaceuticals Announces $1M Private Placement Of 574,713 Shares At $1.74, Including Warrants
Benzinga · 07/30 18:26
Press Release: 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
Dow Jones · 07/30 18:23
*60 Degrees Pharmaceuticals Announces Private Placement Priced At-the-Market Under Nasdaq Rules
Dow Jones · 07/30 18:23
60 Degrees Pharma babesiosis interim readout planned by October 6
TipRanks · 07/29 21:15
60 Degrees Pharmaceuticals Will Be Issued US Patent Number 12,691,107 Tomorrow Titled "METHODS FOR THE TREATMENT AND PREVENTION OF LUNG INFECTIONS CAUSED BY GRAM-POSITIVE BACTERIA, FUNGUS, OR VIRUS BY ADMINISTRATION OF TAFENOQUINE".
Benzinga · 07/27 19:58
Weekly Report: what happened at SXTP last week (0720-0724)?
Weekly Report · 07/27 10:15
60 Degrees updates strategy for ARAKODA and profitability
TipRanks · 07/20 20:34
Weekly Report: what happened at SXTP last week (0713-0717)?
Weekly Report · 07/20 10:11
Weekly Report: what happened at SXTP last week (0706-0710)?
Weekly Report · 07/13 10:13
Interim Trial Plan Finalized for Tafenoquine Babesiosis Study
TipRanks · 07/09 20:31
60 Degrees Pharma Signs FSU Deal To Advance Castanospermine For Tick-Borne Diseases
NASDAQ · 07/09 08:14
More
Webull provides a variety of real-time SXTPW stock news. You can receive the latest news about 60 Degrees Pharm through multiple platforms. This information may help you make smarter investment decisions.
About SXTPW
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.